RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus†or the "Company†), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary results for its fiscal year 2025 and issued preliminary guidance and management outlook for fiscal year 2026 as follows: Fiscal 2025 Preliminary Fiscal 2026 Guidance Revenue  . ...

Market Overview - Global equity markets experienced positive returns in Q3, driven by progress in U.S. tariff negotiations and expectations of Federal Reserve rate cuts, with the MSCI World Growth Index up 8.6% compared to 7.3% for the MSCI World Index and 5.8% for the MSCI World Value Index [2] - Emerging markets showed notable strength, particularly in China, Mexico, and Brazil, with China's tech giants like Tencent and Alibaba contributing to optimism in AI development [5][6] - Developed markets saw Japan leading returns due to clarity on trade policy and confidence in economic resilience, while the eurozone lagged due to political volatility and infrastructure spending debates [6] Quarterly Performance - The ClearBridge Global Value Improvers Strategy generated positive absolute returns but underperformed its benchmark, with industrials and energy holdings detracting from performance [7][19] - Negative stock selection in industrials was primarily due to CNH Industrial's decline amid weaker agricultural demand, while Hitachi remained a strong performer in Japan [8] - Energy stock selection faced challenges from declining commodity prices, with EQT's shares affected by high storage inventories and concerns over demand growth [9] - IT sector stock selection was a strong contributor, particularly Oracle, which gained market share among hyperscalers [10] - In healthcare, CVS and AstraZeneca saw strong performance due to better-than-expected earnings and reduced tariff concerns [11] Portfolio Positioning - New positions were initiated in Lloyds Banking Group, expected to deliver higher normalized returns and a double-digit shareholder yield, and Alphabet, which is positioned to benefit from generative AI developments [13][14] - The strategy exited its position in Novo Nordisk due to lowered full-year guidance and management changes [15] Outlook - Market confidence is bolstered by clarity around tariffs and fiscal policy, although valuations have returned to elevated levels [16] - The focus remains on undervalued companies with distinct growth drivers or restructuring catalysts [16] Energy Sector Insights - Structural shifts in energy demand and efficiency present compelling opportunities, particularly in renewables and energy storage [17] - Companies like Vertiv and Johnson Controls are positioned to benefit from rising energy costs and net-zero goals, with efficiency becoming a competitive advantage [26] ESG Highlights - Carbon capture and sequestration (CCS) technologies are critical for heavy industries, with ClearBridge holdings actively developing CCS capabilities [22][23] - Linde is well-positioned in clean hydrogen production, leveraging its technology to drive emissions savings and business growth [24][30] - Green Plains is focusing on carbon capture initiatives to decarbonize its biorefineries, partnering on projects to sequester significant CO2 emissions [38][40]

Core Insights - Artisan Partners' "Artisan Mid Cap Fund" reported strong performance in Q3 2025, with the Investor Class fund returning 8.80%, Advisor Class fund also at 8.80%, and Institutional Class fund at 8.83%, significantly outperforming the Russell Midcap Growth Index's return of 2.78% [1] - The fund's outperformance was primarily driven by holdings in the health care sector, particularly highlighting Argenx SE (NASDAQ:ARGX) as a top contributor [1][3] Fund Performance - Global equity markets showed strength in Q3 2025, ending the period with double-digit year-to-date gains [1] - The Artisan Mid Cap Fund's returns for the different classes were as follows: Investor Class (ARTMX) 8.80%, Advisor Class (APDMX) 8.80%, and Institutional Class (APHMX) 8.83% [1] Company Spotlight: Argenx SE - Argenx SE (NASDAQ:ARGX) is a commercial-stage biopharma company with a one-month return of 10.70% and a 52-week gain of 50.38%, closing at $812.95 per share with a market capitalization of $149.06 billion on October 14, 2025 [2] - Argenx's VYVGART®, a first-in-class autoimmune therapy, has shown strong growth, supported by a new subcutaneous formulation for self-administration, and is being studied for multiple autoimmune disorders [3] Hedge Fund Interest - Argenx SE (NASDAQ:ARGX) was held by 53 hedge fund portfolios at the end of Q2 2025, a slight decrease from 54 in the previous quarter, indicating a stable interest among hedge funds [4]

Market Overview - The market is performing well, primarily driven by AI advancements, with slow economic growth and rising consumer spending, particularly among high-income individuals [1][2] - Business investment remains stable, and corporate earnings growth is in double digits, creating a favorable economic outlook [2] Investment Strategies - Investing in the healthcare sector is recommended as it has underperformed in recent years, with companies like Danaher and Medpace being highlighted for their resilience against economic fluctuations [4][5] - Blackstone is favored due to its dependence on capital markets, benefiting from lower interest rates and a favorable IPO market, along with significant investments in AI data centers [7][8] Company Analysis - Danaher and Medpace are seen as economically insensitive, with their business driven by drug development cycles and R&D spending, making them attractive investments despite economic uncertainties [5][6] - Blackstone is noted for its strong track record in investment performance, new product development, and capital allocation that benefits shareholders through dividends [10][11] Technology Sector Insights - Nvidia is identified as a top investment due to the increasing demand for AI infrastructure, with expectations for capital expenditure from major tech companies to rise [12][13] - The AI sector is expected to continue leading the market, with significant growth in usage from major players like Google and OpenAI [15][16] Long-term Investment Perspective - For investors with a time horizon beyond five years, equities are considered a better option than bonds, despite the inherent volatility of the stock market [18][19]

Market Overview - The trading day ended with significant declines across major indices, with the S&P 500 down approximately 180 points or 2.7%, marking its worst day since April 10th [7] - The NASDAQ 100 and NASDAQ composite both fell over 3%, also their worst performance since April 10th [7] - The Russell 2000 index dropped more than 74 points or 3% [7] Sector Performance - The technology sector was particularly hard hit, declining about 4%, with semiconductor stocks experiencing notable losses [9] - Consumer staples were the only sector to show positive performance, up about 0.33%, indicating a defensive trade [8][9] - A broad-based sell-off was observed, with 1,425 stocks declining compared to only 78 advancing [8] Company-Specific Movements - MP Materials and USAA, involved in rare earths, saw their stocks rise by 8.5% and 5% respectively, following China's new export curbs [10][11] - Protagonist Therapeutics shares surged nearly 30% after reports of Johnson & Johnson's interest in acquiring the company [13] - Applied Digital's shares increased by over 16% due to positive earnings and advanced talks for a new data center [14] Notable Declines - Levi Strauss experienced a 12% drop, its worst intraday decline since April, after its earnings guidance fell short of expectations [16][17] - Venture Global's stock plummeted nearly 25% following a legal dispute loss with BP, which could have significant financial implications [18] - The VanEck Semiconductor ETF fell almost 6% despite being up 34% year-to-date [19] Economic Context - The market's downturn coincided with concerns over a potential U.S. government shutdown, which has limited the release of economic data [20][27] - Upcoming earnings reports from major banks, including Goldman Sachs and Bank of America, are anticipated to provide insights into consumer spending and economic health [28][29]

Core Viewpoint - Halozyme Therapeutics (HALO) stock is positioned as a strong investment opportunity due to its robust margins, low-debt capital structure, reasonable valuation, and strong momentum [2][3]. Financial Performance - Revenue Growth: Halozyme Therapeutics reported a revenue growth of 35.0% for the last twelve months (LTM) and an average growth of 35.5% over the past three years [6]. - Long-Term Profitability: The company has maintained an operating cash flow margin of approximately 44.7% and an operating margin of 47.8% averaged over the last three years [6]. Market Position - Strong Momentum: HALO is currently in the top 10 percentile of stocks based on a proprietary momentum metric, indicating strong trend strength [6]. - Valuation: Despite its positive momentum, HALO stock is trading 17% lower than its 52-week high, suggesting potential for further growth [6]. Investment Strategy - Selection Criteria: The investment strategy focuses on stocks with a market cap exceeding $2 billion, high operating and cash flow margins, no significant revenue decreases in the past five years, reasonable valuations, low-debt capital structures, and robust momentum [5]. - Historical Performance: Stocks adhering to this selection strategy have shown average 12-month forward returns nearing 15% [5]. Risk and Resilience - Historical Volatility: HALO has experienced significant declines in the past, including a 74% drop during the Global Financial Crisis and a nearly 49% drop during the Inflation Shock [8]. - Recovery Potential: The stock has historically rebounded from sharp declines, indicating resilience despite market volatility [9].

Core Insights - Novo Nordisk (NVO) stock has experienced volatility since Liberation Day, showing a slower recovery compared to other biopharma stocks [1] - The S&P and Eli stocks have performed better year to date, indicating a disparity in market performance within the biopharma sector [1] Company Analysis - The company has a strong foundation in scientific research, with a focus on drug development challenges and the rigor involved [1] - The analyst emphasizes the importance of identifying biotechnology companies that are innovating through unique mechanisms, first-in-class therapies, or platform technologies [1] - The approach combines scientific expertise with financial and market analysis to deliver technically sound and investment-driven research [1] Industry Perspective - The biotech sector is characterized by the potential for breakthrough science to yield significant returns, but it also requires careful scrutiny of opportunities and risks [1] - The analysis will cover companies at various stages of development, from early clinical pipelines to commercial-stage biotechs, highlighting the competitive landscape and market opportunities [1]

Market Overview - U.S. stocks traded higher, with the Dow Jones index gaining approximately 0.2% to 46,532.02, NASDAQ rising 0.34% to 22,833.17, and S&P 500 increasing 0.07% to 6,715.87 [1] - European shares were mostly higher, with the eurozone's STOXX 600 gaining 0.53%, while Spain's IBEX 35 Index fell 0.27% [6] - Asian markets closed higher, with Japan's Nikkei 225 gaining 0.87% and Hong Kong's Hang Seng index gaining 1.61% [9] Company Earnings - AngioDynamics, Inc. reported better-than-expected earnings for Q1, with losses of 10 cents per share, beating the analyst consensus estimate of 12 cents per share. Quarterly sales were $75.711 million, exceeding the consensus estimate of $72.725 million [2] Commodity Prices - Oil prices decreased by 2.1% to $60.47, gold fell by 0.7% to $3,869.20, silver dropped 2.7% to $46.415, while copper rose by 1.2% to $4.9430 [5] Notable Stock Movements - Aspire Biopharma Holdings Inc shares surged 110% to $0.45 following the announcement of a milestone roadmap targeting FDA submission [8] - Canaan Inc shares increased by 25% to $1.30 after announcing a significant sales order [8] - Ondas Holdings Inc shares rose 26% to $9.19 after announcing an initial order of 500 Wasp drones [8] - Uni-Fuels Holdings Ltd shares dropped 72% to $1.42, and Nvni Group Ltd shares fell 50% to $0.37 due to a reverse stock split announcement [8] - FlexShopper Inc shares decreased by 49% to $0.29 following the resignation of its Director amid financial issues [8] Employment Data - U.S.-based employers announced 54,064 job cuts in September, a decrease from 85,979 in August [10]

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.2% on Thursday.The Dow traded up 0.20% to 46,532.02 while the NASDAQ rose 0.34% to 22,833.17. The S&P 500 also rose, gaining, 0.07% to 6,715.87.Check This Out: Cramer Says Arista’s ‘Doing So Well’ — But Snubs Sprouts For CostcoLeading and Lagging SectorsMaterials shares jumped by 1% on Thursday.In trading on Thursday, energy stocks fell by 0.8%.Top HeadlineAngioDynamics, Inc. (NASDAQ:ANGO) reported better-than-exp ...

Market Overview - U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points, the Dow up 0.15% to 46,510.40, the NASDAQ rising 0.47% to 22,861.86, and the S&P 500 increasing 0.27% to 6,729.47 [1] - Information technology shares increased by 0.9%, while real estate stocks fell by 0.6% [1] Company Earnings - AngioDynamics, Inc. reported better-than-expected earnings for Q1, with losses of 10 cents per share, beating the analyst consensus estimate of 12 cents per share. Quarterly sales were $75.711 million, exceeding the consensus estimate of $72.725 million [2] - The company raised its FY26 adjusted EPS and sales guidance [2] Commodity Prices - Oil traded down 1% to $61.20, while gold rose 0.5% to $3,916.00. Silver increased by 0.4% to $47.875, and copper rose 1.1% to $4.9375 [5] Global Market Performance - European shares were higher, with the eurozone's STOXX 600 gaining 0.7%, Spain's IBEX 35 up 0.1%, London's FTSE 100 down 0.1%, Germany's DAX 40 up 1.4%, and France's CAC 40 rising 1.4% [6] - Asian markets closed higher, with Japan's Nikkei 225 gaining 0.87% and Hong Kong's Hang Seng index up 1.61% [7] Stock Movements - Aspire Biopharma Holdings Inc shares surged 81% to $0.39 after announcing a milestone roadmap for FDA submission [9] - Concorde International Group Ltd shares increased by 41% to $3.64, while Iveda Solutions Inc shares rose 39% to $1.89 [9] - Uni-Fuels Holdings Ltd shares dropped 71% to $1.46, and Nvni Group Ltd shares fell 53% to $0.35 following a reverse stock split announcement [9] - FlexShopper Inc shares decreased by 45% to $0.31 after the resignation of its Director due to financial matters [9] Employment Data - U.S.-based employers announced 54,064 job cuts in September, a decrease from 85,979 in August [10]